Background:

Obesity is a global health concern which is continually increasing and contributing to various comorbidities such as type 2 diabetes, COPD, hypertension, and cardiovascular diseases. Medicines such as orlistat are commonly prescribed within primary care settings to aid weight management by reducing fat absorption. The effectiveness of orlistat was reviewed, with a focus on lowering Body Mass Index (BMI).  

Aim of the case report:

This case series aims to evaluate the impact of orlistat on BMI reduction and document potential improvements in comorbidities among patients in our rural primary care settings.

Case report:

The patient's experience and clinical outcomes were assessed by reviewing their ERS records.  A group of patients with a BMI over 35 kg/m² were prescribed orlistat in conjunction with dietary modifications and increased physical activity. Weight reviews were performed within the practice every 3 months following the commencement of orlistat, with good compliance being the key requirement. Patients must have achieved at least 5% weight loss to continue orlistat after 3 months. Significant improvements were observed in weight reduction, allowing for better control of comorbidities and potentially enhancing clinical outcomes. Working in collaboration can achieve a healthy BMI. Regular follow-up consultations highlighted the patient’s increased motivation, accountability, and adherence to lifestyle changes, which may contribute to health improvement. 

Conclusions:

The findings presented in this case series suggest that orlistat may be an effective option in primary care settings for facilitating weight management. Additionally, orlistat has a favourable influence on other chronic conditions that can precipitate deterioration. By focusing on reducing BMI and emphasising the importance of weight management strategies, orlistat can improve patient outcomes, particularly in rural primary healthcare settings.